cancer drug development
Concr Adds Former AstraZeneca and Cancer Research Institute Executives to Advisory Board
Concr; AstraZeneca; Cancer Research Institute; advisory board; biotech; oncology; executive appointments; life sciences; strategic advisory; cancer drug development
Blackstone Pays Merck $700M to Fund Development of Antibody-Drug Conjugate
Blackstone; Merck; sacituzumab tirumotecan; antibody-drug conjugate; cancer drug development; funding agreement; oncology; royalties